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Abstract
Chronic intraperitoneal injection of thioacetamide (TAA) in rats has been used
as an animal model of human cirrhosis to study the effects of the disease on
drug metabolism. However, TAA inhibits P450 enzymes directly and independently of cirrhosis. We investigated the effects of chronic cirrhosis in rats,
induced by 10 weeks of intraperitoneal TAA, on the P450 enzymes after a
10-day washout period to eliminate TAA. Liver histology and serum biomarkers of hepatic function confirmed cirrhosis in all animals. Microsomal
total P450 content, P450 reductase activity and ethoxycoumarin O-deethylase
activity, a general marker of P450 activity, were significantly reduced by 30%–
50% in cirrhotic animals. Additionally, the protein content and Michaelis–
Menten kinetics of the activities of CYP2D, CYP2E1 and CYP3A were investigated. Whereas cirrhosis reduced the microsomal protein contents of CYP2D
and CYP3A by 70% and 30%, respectively, the protein contents of CYP2E1
were not affected. However, the activities of all the tested isoenzymes were
substantially lower in the cirrhotic livers. It is concluded that the TAA model
of cirrhosis that incorporates a 10-day washout period after intraperitoneal
injection of the chemical to rats produces isoenzyme-selective reductions in
the P450 proteins or activities, which are independent of the direct inhibitory
effects of TAA.
KEYWORDS
animal model, CYP2D, CYP2E1, CYP3A, cytochrome P450, fibrosis, liver cirrhosis,
Michaelis–Menten kinetics, thioacetamide
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1 | INTRODUCTION
Liver cirrhosis is a common disease worldwide, with a
prevalence of >1 million patients in the United States
alone.1 Patients with liver cirrhosis usually receive several drugs both for the management of cirrhosis and also
for other associated diseases and comorbidities.2,3 However, liver cirrhosis significantly affects the drug metabolism and clearance in the liver through multiple
mechanisms, including changes in the metabolic activity
of the cytochrome P450 (P450) enzymes, liver blood flow,
biliary excretion and protein binding of drugs.4–6 Indeed,
it has been reported that patients with liver cirrhosis
experience a high frequency of adverse drug reactions
and hospitalization.7 Therefore, it is necessary to study
the mechanisms and effects of cirrhosis-induced changes
in the hepatic clearance of drugs in order to improve drug
therapy and dosage adjustments in these patients.
Several chemicals and surgical procedures have been
used to generate hepatic cirrhosis models in experimental
animals, including rodents.8–14 Among these models, thioacetamide (TAA), an organosulfur chemical, has been widely
used8–10,15 because the histopathological changes in the
TAA-treated animals are similar to those observed in
human cirrhosis.9 To induce cirrhosis, TAA is usually
administered orally, in drinking water, or injected intraperitoneally. Both models require chronic administration of
TAA. However, the drinking water models usually require
longer term administration of TAA (e.g., 6 months)8,16,17
and generally result in less reproducible cirrhosis than the
models utilizing intraperitoneal injection of the chemical.8
In agreement with the reduced metabolic activity of
P450 enzymes in human cirrhosis, previous studies using
TAA-induced cirrhosis in rodents have also shown
decreases in the activities of some hepatic P450 enzymes
in cirrhotic animals.16,18–20 However, it has been
reported21,22 that the in vivo administration of TAA or its
S-oxide metabolite significantly decreases the liver P450
activities acutely (within 12 h), which is independent of
the cirrhosis-inducing effects of TAA. Further, another
study18 showed that the direct addition of TAA to the rat
liver microsomes caused significant decreases in the
activities of several P450 isoenzymes, which was NADPH
dependent, suggesting a mechanism-based inactivation of
P450 by TAA metabolites. Collectively, these data indicate the need for a washout period for the TAA model to
separate the direct mechanism-based inhibition of P450
activities by TAA from the P450 inhibitory effects of the
disease (cirrhosis) itself. Few studies16,23 have reported
the effects of TAA-induced cirrhosis on the P450 enzymes
after a washout period. However, these studies were carried out after oral administration of TAA in the drinking
water, which requires longer treatment periods and is not
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as reproducible as the ip injection of the chemical to
induce cirrhosis. Therefore, the purpose of the current
study was to test the effects of experimental cirrhosis
caused by the more reproducible ip injection of TAA in
rats after a 10-day washout period to eliminate the chemical and its direct effects on the P450 enzymes. We determined the Michaelis–Menten kinetics of major P450
enzymes in relation to their protein contents in the liver
of cirrhotic animals and their control counterparts. We
hypothesized that in the absence of mechanism-based
direct effects of TAA, the TAA-induced cirrhosis in rats,
similar to human cirrhosis, would result in reductions in
protein contents and activities of P450 isoenzymes.

2 | MATERIALS AND METHODS
2.1 | Chemicals and reagents
TAA, cytochrome-c, NADPH, 7-ethoxycoumarin, 7hydroxycoumarin, chlorzoxazone, 6-hydroxychlorzoxazone
and 4-hydroxymidazolam (4-OH-MDZ) were purchased
from Sigma-Aldrich (St. Louis, MO, USA). Dextromethorphan and midazolam (MDZ) were procured from the
United States Pharmacopeial Convention (Rockville, MD,
USA). Analytical metabolite standard 10 -hydroxymidazolam
(10 -OH-MDZ), dextrorphan tartrate and the stable isotopes
dextrorphan-d3 and 7-hydroxycoumarin-d5 were purchased
from Cerilliant Corporation (Round Rock, TX, USA).
The other stable isotopes 10 -hydroxymidazolam-d5 and
4-hydroxymidazolam-d5 methanoate were purchased from
Toronto Research Chemicals (North York, ON, Canada).
The stable isotope 6-hydroxychlorzoxazone-d2 was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA).
Primary antibodies raised in rabbits against CYP2D1
(ab22590; RRID:AB_447177), CYP2E1 (ab84598; RRID:AB_
10673797) and calreticulin (ab92516; RRID:AB_10562796)
were purchased from Abcam (Cambridge, MA, USA), while
the primary antibody raised in mice against CYP3A (D2:
sc271033; RRID:AB_10614144) was purchased from Santa
Cruz Biotechnology (Santa Cruz, CA, USA). The secondary
antibody HRP-conjugated goat anti-rabbit IgG H&L
(ab6721; RRID:AB_955447) and HRP-conjugated goat antimouse IgG H&L (ab6789; RRID:AB_955439) were purchased from Abcam. All the other chemicals and reagents
were procured from commercially available sources.

2.2 | Animals and experimental design
Male Sprague–Dawley rats, weighing around 150–180 g,
were procured from Charles River Laboratories
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(Wilmington, MA, USA). The rats were housed in a
temperature- and humidity-controlled room under a
12-h light–dark cycle with free access to food and
water ad libitum. The animals were acclimated at the
animal facility for a week before starting the experiments. The animals were randomly divided into two
groups, with seven rats in each group. TAA, dissolved
in saline, was injected intraperitoneally (200 mg/kg,
3 days a week for 10 weeks) to the TAA group to
induce cirrhosis, while the control group received
saline injections. At the end of TAA treatment, the
animals were allowed a 10-day washout period to
remove residual TAA, followed by the collection of
blood samples through cardiac puncture under isoflurane anaesthesia. After cardiac perfusion with cold
saline, the liver samples were collected, snap-frozen in
liquid nitrogen and stored at 80 C.
The study was conducted in accordance with the
Basic & Clinical Pharmacology & Toxicology policy for
experimental and clinical studies.24 Additionally, the
Institutional Animal Care and Use Committee of
Chapman University approved all the experimental
animal procedures.

2.3 | Serum biochemical and liver tissue
histopathological analysis
The serum was separated from the blood samples collected from the saline- and TAA-treated groups. The
serum samples were utilized for the quantitation of the
liver biomarkers albumin, alanine aminotransferase
(ALT), aspartate aminotransferase (AST), total bilirubin
(TBil), alkaline phosphatase (ALP) and γ-glutamyl
transferase (GGT) by an automated blood chemical
analyser.
For histological studies, sections of the livers from
both saline- and TAA-treated groups were taken and
fixed in phosphate-buffered 10% formaldehyde solution,
followed by embedding in paraffin wax. Sections of the
liver tissues (5-μm thickness) were stained with
haematoxylin–eosin (to assess necrotic inflammation)
and Masson’s trichrome (to assess fibrosis). They were
examined for histopathological changes under the microscope, and their photomicrographs were captured. Histological grading for necro-inflammatory activity and
fibrosis staging was done according to the Knodell scoring system.25,26 The necro-inflammatory activity has a
maximum score of 18, consisting of periportal bridging
necrosis (0–10), intralobular degeneration and focal
necrosis (0–4) and portal inflammation (0–4). The fibrosis
score has a grade range of zero (no fibrosis) to 4 (cirrhosis). The grader was blinded to the treatment of samples.

3

2.4 | Preparation of microsomes
Rat liver microsomes were prepared using the differential
centrifugation technique. Frozen liver samples were
weighed and homogenized (1:10, w/v) in ice-cold buffer
(250-mM Mannitol, 0.1-mM EDTA, 5-mM HEPES, pH 7.4).
The homogenate was spun at 600 g at 4 C for 5 min to
separate the large debris and nuclei. The supernatant was
collected and centrifuged at 10 300 g at 4 C for 10 min to
remove mitochondria. The supernatant (cytosol and microsomes) was collected and centrifuged at 110 000 g at 4 C
for 70 min. The resulting microsomal pellet was washed
and resuspended in 2 ml of storage buffer (250-mM
Mannitol, 0.1-mM EDTA, 5-mM HEPES, 20% glycerol,
0.1-mM dithiothreitol, 22-μM butylated hydroxytoluene and
0.1-mM phenylmethylsulfonylfluoride; pH 7.4) and preserved at 80 C for further experiments. The total protein
concentrations were estimated using the Bradford method.

2.5 | Western blot analysis
The protein expressions of the major rat cytochrome P450
isoenzymes in the liver microsomal fractions were determined by Western blot analysis. In brief, the liver microsomal samples (0.5- to 5-μg protein/lane) were separated by
SDS-polyacrylamide gel electrophoresis on a precast BioRad (Hercules, CA, USA) 12% MP TGX gels at a constant
voltage (200 V) for 30 min. Proteins were transferred with
the Bio-Rad Trans-Blot Turbo Transfer System onto
0.45-μm polyvinylidene fluoride (PVDF) membranes. The
PVDF membranes were blocked with 5% BSA (for CYP2D
or CYP2E1) or ultra-blocking reagent (for CYP3A) for 1 h
at room temperature. The blots were then incubated (4 C)
overnight with primary antibodies diluted in 5% BSA in
wash buffer for CYP2D (1:10 000) or CYP2E1 (1:10 000).
CYP3A blots were incubated for 1 h with the diluted
(1:400) primary antibody. After washing, the blots were
incubated with HRP-conjugated goat anti-rabbit (CYP2D
[1:5000] and CYP2E1 [1:50000]) or HRP-conjugated goat
antimouse (CYP3A [1:2500]) secondary antibodies for 1 h
at room temperature and washed before visualization of
bands with the Bio-Rad Chemi Doc Imager system.
After imaging for CYP2D, CYP2E1 and CYP3A, the
membranes were stripped to detect calreticulin (endoplasmic reticulum marker) as a loading control. For stripping,
the membranes were washed with wash buffer and incubated with Restore™ Western blot stripping buffer
(ThermoFisher Scientific, Waltham, MA, USA) for 15 min
at room temperature with gentle shaking. After washing,
membranes were blocked with 5% BSA and probed with an
anti-calreticulin antibody (1:1000) at 4 C overnight.
Subsequently, the membranes were incubated with the
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HRP-conjugated goat anti-rabbit (1:5000) secondary
antibody for 1 h at room temperature, and the
chemiluminescence was detected using a Bio-Rad imager.

2.6 | P450 reductase activity and total
P450
Microsomal P450 reductase activity was quantitated
using established methods, based on the reduction of
cytochrome c.27 Total P450 content of the liver microsomes was estimated based on the carbon monoxide difference spectrum method of Omura and Sato28 and
expressed as nanomoles per milligram of protein.

100-mM Tris–HCl buffer (pH 7.4), at a protein concentration of 0.05 mg/ml, using the substrate (dextromethorphan)
at different concentrations (0.25, 0.5, 2.5, 5, 10, 50, 100,
200 and 500 μM). The reaction mixtures (25 μl) contained
buffer, liver microsomes and the substrate. After 5 min of
preincubation at 37 C, the reaction was initiated by the
addition of 1-mM NADPH. After 5 min of incubation at
37 C, reactions were terminated by the addition of ice-cold
acetonitrile (75 μl), containing 200-nM internal standard
(dextrorphan-d3). Samples were centrifuged, and the supernatant was used for the LC-MS/MS analysis.

2.7.3 |

Chlorzoxazone 6-hydroxylase activity

Enzymatic activities of P450 isoenzymes were characterized
based on the following reactions: ethoxycoumarin Odeethylation (ECOD) activity as a general marker of P450
dextromethorphan
O-demethylation
for
activity,29
CYP2D,30 chlorzoxazone 6-hydroxylation for CYP2E130 and
midazolam 10 -hydroxylation and 4-hydroxylation for
CYP3A.31 For each probe drug, preliminary experiments
were performed to determine whether metabolite formation
rates were linear with the incubation time and microsomal
protein concentrations. For all the assays, the percentage of
metabolite conversion was less than 10% of substrate added.

The assay for chlorzoxazone-6-hydroxylation activity
was carried out based on the formation of
6-hydroxychlorzoxazone in a 100-mM Tris–HCl buffer
(pH 7.4), at a protein concentration of 0.4 mg/ml, using
the substrate (chlorzoxazone) at various concentrations
(0.5, 1, 5, 10, 50, 100, 250, 500 and 1000 μM). The reaction
mixtures (50 μl) contained buffer, liver microsomes and
the substrate. After 5 min of preincubation at 37 C, the
reaction was initiated by the addition of 1-mM NADPH.
After 5 min of incubation at 37 C, reactions were
terminated by the addition of ice-cold acetonitrile
(150 μl), containing 20-nM internal standard (6-hydroxy
chlorzoxazone-d2). Samples were centrifuged, and the
supernatant was subjected to the LC-MS/MS analysis.

2.7.1

2.7.4 |

2.7 | P450 enzymatic activities

| ECOD activity

The assay for ECOD activity was carried out based on the
formation of 7-hydroxycoumarin, in a 0.1-M phosphate
buffer (pH 7.4), at a protein concentration of 0.05 mg/ml
using the substrate (7-ethoxycoumarin) at two concentrations of 50 and 500 μM. The reaction mixtures (100 μl)
contained buffer, liver microsomes and the substrate.
After 5 min of preincubation at 37 C, the reaction was
initiated by the addition of 1-mM NADPH. After 10 min
of incubation at 37 C, reactions were terminated by the
addition of ice-cold acetonitrile (300 μl), containing
400-nM internal standard (7-hydroxycoumarin-d5). Samples were centrifuged, and the supernatant was used for
the LC-MS/MS analysis.

Midazolam hydroxylation activity

The assay for midazolam hydroxylation activity was
carried out based on the formation of 10 -OH-MDZ and
4-OH-MDZ, in a 100-mM Tris–HCl buffer (pH 7.4), at a
protein concentration of 0.025 mg/ml, using the substrate
(midazolam) at different concentration (0.5, 2, 5, 10, 20,
50, 100 and 200 μM). The reaction mixtures (50 μl) contained buffer, liver microsomes and the substrate. After
5 min of preincubation at 37 C, the reaction was initiated
by the addition of 1-mM NADPH. After 10 min of incubation at 37 C, reactions were terminated by the addition of
ice-cold acetonitrile (150 μl) containing 20-nM internal
standards (10 -OH-MDZ-d5 and 4-OH-MDZ-d5). Samples
were centrifuged, and the supernatant was subjected to
the LC-MS/MS analysis.

2.7.2 | Dextromethorphan O-demethylase
activity

2.8 | Analytical methods

The assay for dextromethorphan O-demethylase activity
was carried out based on the formation of dextrorphan, in a

The
metabolites
7-hydroxycoumarin,
dextrorphan,
6-hydroxychlorzoxazone and 10 - and 4-hydroxymidazolam
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and their respective deuterated internal standards were analysed by UPLC-tandem mass spectroscopy. The UPLC-MS/
MS system consisted of a Bruker EVOQ triple quadrupole
mass spectrometer coupled to the Bruker Advance UPLC
system equipped with an integrated column oven, degasser
and a CTC PAL autosampler. The system was controlled,
and the data were acquired and quantified by the Bruker
MSWS-8 software.
The chromatographic separation of 7-hydroxycoumarin,
dextrorphan or 6-hydroxychlorzoxazone and their respective deuterated internal standards was achieved using a
5-cm-long Phenomenex Kinetex 1.7 μm C18 (100 A,
50  2.1 mm) column, connected to a Phenomenex C18
Security Guard ULTRA (2.1 mm) pre-column maintained
at 40 C. 10 -Hydroxymidazolam, 40 -hydroxymidazolam and
their deuterated internal standards were separated on a
10-cm-long Phenomenex Kinetex 1.7 μm C18 (100 A,
100  2.1 mm) column.
All the processed samples (2 μl) were injected onto
the column and eluted at a flow rate of 0.2 ml/min under
gradient conditions consisting of solvent A (5-mM
ammonium formate:formic acid 100:0.05) and solvent B
(acetonitrile:methanol:formic acid, 95:5:0.05). The mass
spectrometer was equipped with an electrospray ionization source heated at 300 C. The common parameters
like cone, probe and nebulizer gas flow were set at
20, 40 and 50 psi, respectively. Quantitation was achieved
by MS/MS detection in positive ion mode set at 3000-V
ion spray voltage for dextrorphan, 10 -hydroxymidazolam
and 4-hydroxymidazolam, while for 7-hydroxycoumarin
and 6-hydroxychlorzoxazone, the quantitation was
achieved in negative ion mode where the ion spray
voltage was set at 3000 V. The detailed MS conditions,
collision energy and the respective retention times are
summarized in Table 1. Additionally, the linear
(r 2 ≥ 0.99) range of calibration curves and the lower limit

TABLE 1
standards

of quantitation (LLOQ) of the analytes are presented in
Table 2.

2.9 | Data analysis
Data analysis was conducted using GraphPad Prism
software (La Jolla, CA, USA). For the estimation of the
Michaelis–Menten kinetic parameters, the formation
rates of metabolites were plotted against the substrate
concentrations. Subsequently, the data were fitted to the
following two equations for a one- or two-enzyme kinetic
model using nonlinear regression analysis:
Formation Rate ¼

Formation Rate ¼

V MAX  C
KM þ C

V MAXð1Þ  C V MAXð2Þ  C
þ
K M ð1Þ þ C
K M ð2Þ þ C

where VMAX and KM refer to the maximum velocity and
Michaelis–Menten constant, respectively; C refers to the
T A B L E 2 The linear (r2 ≥ 0.99) range of calibration curves
and the lower limit of quantitation (LLOQ) of the studied
metabolites
Metabolite

Calibration range
(nM)

LLOQ
(nM)

7-Hydroxycoumarin

10–1000

10

Dextrorphan

10–2000

10

5–7500

5

6-Hydroxychlorzoxazone
10 -Hydroxymidazolam

2.5–500

2.5

4-Hydroxymidazolam

2.5–500

2.5

Mass spectrometric conditions for the metabolites generated by the P450 substrates and their respective deuterated internal

Analyte

Precursor (Q1)

Product (Q3)

Collision energy (V)

Retention time (min)

7-Hydroxycoumarin

160.9

132.9

15.0

3.12

7-Hydroxycoumarin-d5

166.0

137.9

17.0

3.11

Dextrorphan

258

156.9

39.0

2.52

Dextrorphan-d3

261

156.9

39.0

2.52

6-Hydroxychloroxazone

184

120.0

16.0

2.81

6-Hydroxychloroxazone-d2

186

121.8

16.0

2.81

10 -Hydroxymidazolam

342

202.9

26.0

5.05

346.9

207.9

26.0

5.05

0

1 -Hydroxymidazolam-d5
4-Hydroxymidazolam

342

234.2

35.0

4.65

4-Hydroxymidazolam-d5

346.9

234.9

23.0

4.65
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substrate concentration and numbers 1 and 2 denote the
enzymes 1 and 2 in a two-enzyme model. The fit of the
data to the two models for each of the metabolites was
compared using the sum-of-squares F test, which selects
the simpler model (single-enzyme model) unless the
p value is less than 0.05.
A comparison of the liver histopathological scores
between the TAA and saline groups was conducted using
the non-parametric Mann–Whitney test. All the other
comparisons between the two groups were conducted
using an unpaired, two-tailed t-test. Differences were
regarded as statistically significant when p was <0.05.
The data are presented as mean  SE.

CHANDRASHEKAR ET AL.

Representative photomicrographs of liver sections of
saline and TAA animals stained with Masson’s trichrome
and haematoxylin–eosin (H&E) are depicted in Figure 2.
Additionally, the average scores for fibrosis (Masson’s
trichrome) and necro-inflammation (H&E) for the two
groups of animals are presented in this figure. As demonstrated (Figure 2), all the TAA livers had the highest
score (4) for fibrosis without any fibrosis for the saline
livers. Further, the necro-inflammatory score in the TAA
group (7.7  0.7) was significantly (p < 0.001) higher
than that in the saline animals (1.7  0.4), confirming
the presence of cirrhosis in the TAA animals.

3.2 | Total CYP450 and CPR activity
3 | R E SUL T S
3.1 | Biochemical and histopathological
parameters
The serum biomarkers of hepatic functions are shown in
Figure 1. Compared with the saline group, the TAAtreated animals showed significant increases in the serum
levels of ALP, GGT, TBil and bile acids and a significant
decrease in the serum albumin levels, indicating the presence of cirrhosis and hepatocyte damage in the TAA
group. However, no significant changes were observed in
the serum levels of ALT, AST and creatinine as a result
of cirrhosis after a 10-day TAA washout period
(Figure 1).

The total 450 content and cytochrome P450 reductase
(CPR) activity in the liver microsomes are presented in
Figure 3. TAA-induced cirrhosis caused significant reductions in both total P450 content (50%, p < 0.01) and the
CPR activity (30%, p < 0.05) in the liver microsomes.

3.3 | Western blot analysis of P450
isoenzymes
The protein contents of CYP2D, CYP2E1 and CYP3A in
the liver microsomal preparations are shown in Figure 4.
For all the isoenzymes, calreticulin was used as the
loading control. The TAA treatment showed significant
reductions in the protein contents of CYP2D (70%,
p < 0.001; Figure 4A) and CYP3A (30%, p < 0.05;
Figure 4C) enzymes as compared with those of the saline
control group. However, there were no significant
changes in the protein levels of CYP2E1 as a result of
TAA-induced cirrhosis (Figure 4B).

3.4 | General and isoenzyme-specific
activity of P450

F I G U R E 1 The effects of TAA-induced cirrhosis on the serum
biomarkers of hepatic function in rats. Animals were treated with
ip injections of 200-mg/kg TAA (n = 7) or saline (n = 7) three
times a week for 10 weeks, followed by a 10-day washout period.
The columns and bars indicate the mean and SE values,
respectively. *, p < 0.05; **, p < 0.01; ***, p < 0.001; two-tailed
unpaired t-test, compared with the saline group. Abbreviations:
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST,
aspartate aminotransferase; GGT, γ-glutamyl transferase; TBil, total
bilirubin

The ECOD activities, as a general marker of P450 activity, at substrate concentrations of 50 and 500 μM are presented in Figure 5. Compared with the saline-treated
animals, the ECOD activities of the liver microsomes of
TAA-treated animals were significantly reduced by
40%–45% (p < 0.05) at the tested substrate concentrations of 50 and 500 μM (Figure 5).
The Michaelis–Menten plots of dextromethorphan Odemethylation, chlorzoxazone 6-hydroxylation and midazolam 10 - and 4-hydroxylation as markers of CYP2D,
CYP2E1 and CYP3A, respectively, in the saline- and
TAA-treated animals are presented in Figure 6.
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F I G U R E 2 Representative photomicrographs of liver sections stained with Masson’s trichrome (A and B) and haematoxylin–eosin
(H&E) (D and E) along with fibrosis (C) and necro-inflammatory (F) scores in rat livers. Animals were treated with ip injections of 200-mg/
kg TAA (n = 7) or saline (n = 7) three times a week for 10 weeks, followed by a 10-day washout period. The columns and bars indicate the
mean and SE values, respectively. ***, p < 0.001; Mann–Whitney test, compared with the saline group

F I G U R E 3 Microsomal total cytochrome
P450 (A) and cytochrome P450 reductase (CPR)
(B) in rat livers. Animals were treated with ip
injections of 200-mg/kg TAA (n = 7) or saline
(n = 7) three times a week for 10 weeks,
followed by a 10-day washout period. The
symbols and horizontal lines indicate the
individual and mean values, respectively. *,
p < 0.05; **, p < 0.01; two-tailed unpaired t-test,
compared with the saline group

Additionally, their respective Michaelis–Menten kinetic
parameters are listed in Table 3. The incubation conditions, including microsomal protein levels and incubation time, were optimized to ensure the linear production
of metabolites for each substrate. The data for dextromethorphan O-demethylation (CYP2D) was best fitted by a
two-enzyme model, indicating the involvement of at least
two enzymes in the metabolism of dextromethorphan in
the rat livers (Figure 6A). However, the best fit for the
chlorzoxazone 6-hydroxylation (CYP2E1) (Figure 6B)

and midazolam 10 - (Figure 6C) and 4- (Figure 6D)
hydroxylation was a single-enzyme model.
Except for the 4-hydroxylation of MDZ, cirrhosis
resulted in significant reductions in the VMAX values for
all the tested microsomal activities (Figure 6 and
Table 3). However, the KM values of the metabolism of
the probe substrates were not significantly affected by
TAA-induced cirrhosis (Table 3). The microsomal highand low-capacity VMAX values for CYP2D demethylase
activity were reduced by 51% (p < 0.05) and 74%

17427843, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/bcpt.13813 by Chapman University, Wiley Online Library on [28/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

CHANDRASHEKAR ET AL.

CHANDRASHEKAR ET AL.

hydroxylase activity, resulting in 10 -hydroxylation of midazolam, was reduced by 71% (p < 0.001). However, a 33%
reduction in the VMAX of midazolam 4-hydroxylation
activity did not reach statistical significance (p = 0.1672)
(Table 3).

4 | DISCUSSION

F I G U R E 4 Western blot images and densitometric data for
microsomal content of CYP2D (A), CYP2E1 (B) and CYP3A
(C) along with their respective loading control calreticulin in TAA
(T)- or saline (S)-treated animals. Animals were treated with ip
injections of 200-mg/kg TAA (n = 7) or saline (n = 7) three times a
week for 10 weeks, followed by a 10-day washout period. For
brevity, the Western blot images are shown for four livers in each
group. The symbols and horizontal lines indicate the individual and
mean values, respectively. *, p < 0.05; ***, p < 0.001; two-tailed
unpaired t-test, compared with the saline group

(p < 0.0001), respectively, in the TAA group (Table 3).
For CYP2E1, cirrhosis caused a 52% reduction in the
VMAX value (p < 0.0001) for the chlorzoxazone hydroxylation activity. The VMAX of microsomal CYP3A

Compared with the other chemically induced cirrhosis
models, the TAA model of liver cirrhosis in rodents is
one of the preferred experimental models of human
cirrhosis because of its reproducibility, low mortality and
reduced toxicity.9 However, different protocols with
regard to the route of administration (oral in drinking
water or intraperitoneal injection), dose/dosing frequency
and length of treatment have been reported in the literature. Our chronic cirrhosis model in rats, which was
based on the intraperitoneal injection of 200-mg/kg TAA
three times a week for 10 weeks, followed by a 10-day
washout period, resulted in substantial necroinflammation and fibrosis of the liver (Figure 2) and significant increases in the plasma levels of the liver injury
markers ALP, GGT and TBil (Figure 1). Additionally, the
plasma levels of bile acids were increased by 24 times in
the TAA group (Figure 1), suggesting the presence of
severe cholestasis. These results are consistent with the
previous reports after intraperitoneal injection of
TAA.10,18,20,32,33 For example, similar to our high necroinflammatory (cirrhosis) and fibrosis scores in the TAA
group (Figure 2), gross cirrhosis and a fibrosis score of
3.98 were reported in rats receiving ip injection of
300-mg/kg TAA, thrice a week for 10 weeks, after a
1-week washout period.32 Similarly, an average fibrosis
score of 3.5 was reported in rats 3 weeks after the cessation of ip injections of 200-mg/kg TAA every other day
for 10 weeks.10 The histological findings in our study
(Figure 2) and these literature data10,32 indicate that the
TAA-induced cirrhosis using these protocols is not
reversible after 1–3 weeks of washout.
Despite large increases in the plasma levels of ALP,
GGT, TBil and bile acids in the TAA group, the plasma
levels of ALT and AST were similar in the saline- and
TAA-treated groups in our study (Figure 1). Although
some studies have reported higher plasma AST and ALT
levels in the TAA-induced cirrhotic rats,18,19,33 others9,20
have shown no significant changes in these markers in
the TAA model. This discrepancy may be related to the
length of TAA treatment. For example, in a time course
study of the effects of repeated ip administration of TAA
to rats, Wallace et al.9 showed that while the plasma
levels of AST and ALT increased sharply during the first
2 weeks of treatment, they returned to normal levels at
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F I G U R E 5 Ethoxycoumarin Odeethylation (ECOD) activities at substrate
concentrations of 50 (A) or 500 (B) μM in rat
livers. Animals were treated with ip injections
of 200-mg/kg TAA (n = 7) or saline (n = 7)
three times a week for 10 weeks, followed by a
10-day washout period. The symbols and
horizontal lines indicate the individual and
mean values, respectively. *, p < 0.05; two-tailed
unpaired t-test, compared with the saline group

F I G U R E 6 Michaelis–
Menten plots of CYP2Dmediated dextromethorphan Odemethylation (A),
CYP2E1-mediated
chlorzoxazone hydroxylation
(B) and CYP3A-mediated
midazolam 10 - (C) and 4(D) hydroxylation in rat liver
microsomes. Animals were
treated with ip injections of
200-mg/kg TAA (n = 7) or
saline (n = 7) three times a
week for 10 weeks, followed by
a 10-day washout period. The
symbols and error bars
represent the mean and SE
values, respectively, and the
lines represent the nonlinear
regression fit of the
experimental data.

Week 4 and remained normal for up to 12 weeks of TAA
treatment. However, the portal pressure, collagen content
and fibrosis-associated genes peaked at Week 8 and
remained high up to 12 weeks of treatment.9 The lack of
changes in the AST/ALT levels in our 10-week TAA
model is in agreement with the latter report and consistent with the reports that AST and ALT levels are more
sensitive to acute liver injury and are often close to the
normal range in patients with cirrhosis.34
Although cirrhosis induced in rats surgically by bile
duct ligation or chemically by carbon tetrachloride causes
substantial (60%) reductions in the serum albumin
concentrations,35 the chronic administration of TAA in
our model caused only 10% decline in the serum albumin levels (Figure 1). The smaller reduction in the albumin concentrations in our animal model is closer to the

10%–20% reductions in the serum albumin concentrations observed in moderate to severe cirrhosis in human
beings.4 Further, our results are in agreement with
previous studies after chronic administration of TAA to
rats,8,33 which showed small or no reductions in the
serum albumin levels. Nevertheless, collectively, our biochemical (Figure 1) and histological (Figure 2) findings
clearly show the presence of liver cirrhosis in our model,
which also has a 10-day washout period.
To test the effects of liver cirrhosis in our rat model
on the overall content and activities of P450, we first
measured the microsomal total P450 contents and
7-ECOD activity that is a measure of activities of multiple
P450 enzymes in CYP1, CYP2 and CYP3 families.29 The
50% and 40%–45% reductions in the total P450 (Figure 3)
and ECOD activity (Figure 5), respectively, in our TAA
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T A B L E 3 Apparent KM and VMAX values (mean  SE, n = 7) for dextromethorphan O-demethylation, chlorzoxazone 6-hydroxylation
and midazolam 10 - and 4-hydroxylation in rat liver microsomal preparations of saline- and TAA-treated groups
Saline group

Enzyme/substrate

VMAX
pmol/(min.mg)

TAA group
KM
μM

VMAX
pmol/(min.mg)

KM
(μM)

CYP2D/dextromethorphan
High affinity

308  63

1.08  0.30

151  29*

1.04  0.09

Low affinity

1040  105

75.5  25.2

274  47****

72.6  18.8

2630  168

190  20

1270  80****

337  82

10 -Hydroxylation

494  64

20.4  2.5

145  30***

15.2  3.5

4-Hydroxylation

1190  235

25.0  5.8

792  128

32.5  7.3

CYP2E1/chlorzoxazone
CYP3A/midazolam

Note: Two-tailed unpaired t-test, compared with the saline group.
*p < 0.05.
***p < 0.001.
****p < 0.0001.

group after 10 days of TAA washout indicate that the
observed effects of P450 are due to cirrhosis and not the
direct effects of the chemical.
Previous in vitro and in vivo studies have shown that
TAA and its metabolite TAA S-oxide reduce the P450
content and activity using mechanisms that are independent of cirrhosis.18,21,22 Hunter et al.21 reported that the
in vivo administration of TAA or its S-oxide metabolite to
rats caused a relatively rapid decrease in the P450 activities, which reached its maximum effect at 24 h. The effect
was dose dependent for both compounds and more pronounced and rapid for the metabolite than the parent
drug.21 In a follow-up study, Matsuura et al.22 reported
that a relatively rapid decrease in the P450 content and
activity by the in vivo administration of both TAA or its
S-oxide metabolite was associated with a rapid induction
of heme oxygenase and inhibition of 5-aminolevulinic
acid synthetase, which is the rate-limiting enzyme in
heme synthesis. Therefore, the authors suggested that the
rapid effects of in vivo administration of TAA or its Soxide metabolites on the P450 enzymes in rats are most
likely due to increased degradation and reduced synthesis
of heme by both compounds. They also showed in a time
course study that after injection of a single ip dose of
150 mg/kg of TAA to rats, P450 concentration and activity declined relatively rapidly, reaching a maximum effect
at 32 h and returning to near control values by 96 h.22
Therefore, in our studies, we chose a 10-day washout
period to separate the effects of the disease (cirrhosis) on
the P450 concentration and activity from the other potential effects of the chemical itself.
It may be argued that the direct effects of TAA on the
degradation and synthesis of heme after multiple doses of
TAA, used in our study, may last longer than that

reported after a single dose of TAA (<96 h).22 Although
this possibility cannot be ruled out, given the very short
in vivo half-lives of TAA and its S-oxide metabolite in rats
(1–2 h),36 it is less likely that the cirrhosis-independent
effects of TAA last longer than our washout period
(i.e., 10 days).
In addition to its effects on heme synthesis and degradation, it has been reported that TAA exerts a
mechanism-based inhibitory effect on P450 enzymes.18
Direct in vitro addition of TAA at different concentrations to rat liver microsomes inhibited the activities of
several P450 isoenzymes in a concentration, time and
NADPH-dependent manner, suggesting a mechanismbased inhibitory activity for TAA. These studies clearly
indicate the need for a washout period in the TAAinduced cirrhosis model to remove the drug and its
metabolites and their mechanism-based inhibitory effects
on P450 enzymes in order to study the effects of liver cirrhosis on drug metabolism.
Studies in human beings with liver cirrhosis have
shown that the disease-induced reductions in the P450
activities are isoenzyme selective.37–39 Similarly, the
results of our study in the TAA model indicate that the
contents (Figure 4) and activities (Figure 6 and Table 3)
of the individual isoenzymes were selectively affected by
the disease. For example, a 50% reduction in the microsomal total P450 (Figure 3A) was associated with 70%
and 30% reductions in the contents of CYP2D
(Figure 4A) and CYP3A (Figure 4C), respectively,
whereas the microsomal contents of CYP2E1 remained
unaffected (Figure 4B). Although the TAA-induced
reductions in the activities of CYP2D and CYP3A were in
agreement with the reductions in their protein contents,
the activities of CYP2E1 were also significantly reduced
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in the TAA group despite no changes in its protein contents (Figures 4 and 6 and Table 3). This discrepancy may
be explained by a significant cirrhosis-induced reduction
in the CPR activity (Figure 3B), which is the rate-limiting
step in the P450-mediated enzymatic reactions. A previous study40 has also reported 20% and 40% reductions in
the CPR activity per milligrams of liver tissue in human
livers with mild and moderate cirrhosis, respectively. Our
results in the TAA model in rats, which showed a 30%
reduction in the CPR activity (Figure 3B), are in agreement with this report40 in human cirrhotic livers.
The decrease in the CYP2E1 activity (Figure 6B)
despite no change in its protein contents (Figure 4B) in
cirrhotic animals may also be related to the posttranslational modifications of this isoenzyme in cirrhotic
animals. For example, it has been reported41 that
whereas the CYP2E1 mRNA and protein contents remain
unaffected in rats from 8 to 18 months of age, the activity
of CYP2E1, measured by chlorzoxazone hydroxylation,
significantly decreases during the same period. This
observation was selective for CYP2E1 because the CYP3A
activity did not change during the same time period, an
observation that was consistent with no change in its
mRNA or protein content. The authors attributed the discrepancy in the protein–activity relationship of CYP2E1
to its protein modifications by age-related oxidative
stress, such as reductions in reduced glutathione and
increases in thiobarbituric acid reactive substances, selectively affecting CYP2E1 and not CYP3A.41 Cirrhosis
induced by TAA is also known to produce oxidative
stress.12 Therefore, similar oxidative stress-induced posttranslational modifications of CYP2E1 protein may have
also contributed to the reduction in the activity of this
enzyme in our cirrhotic animals in the absence of any
changes in its protein.
The reductions in the P450 enzyme content and activities observed in our study after chronic ip administration
of TAA to rats (Figures 3–6 and Table 3) are in general
agreement with the previous reports that used ip
injection of TAA to induce liver cirrhosis in rats.18–20
Nakajimal et al.19 reported that after 8 weeks of ip
injection of TAA (200 mg/kg, three times a week), the
microsomal total P450, the protein contents of several
P450 isoenzymes and the metabolism of nicotine to
cotinine declined significantly. Similarly, Xie et al.18
reported significant reductions in the protein contents of
several P450 isoenzymes 6 weeks after ip injection of
200-mg/kg TAA twice a week. However, both studies18,19
also found a >50% decline in the microsomal CYP2E1
protein, which contrasts with our finding of no change in
the microsomal protein content of this isoenzyme in the
TAA group (Figure 4B). This discrepancy may be related
to the fact that, as opposed to our 10-day washout period,

11

these studies18,19 were conducted in microsomes
prepared soon after the last injection of TAA.
Among P450 isoenzymes, CYP2E1 is unique because
its catalytic cycling in the absence of substrates and inhibitors generates a substantial amount of reactive oxygen species, resulting in its own degradation. Therefore, CYP2E1
is the most unstable microsomal P450 enzyme with a short
half-life of 4–7 h.42 However, substrates and inhibitors of
CYP2E1 increase the half-life of the enzyme several times
by inhibiting its degradation.42 TAA and its S-oxide metabolite are reportedly CYP2E1 substrates, which are converted by CYP2E1 to the highly reactive S,S-dioxide
metabolite that causes hepatic damage. Indeed, a previous
study43 reported that by binding to the active site of
CYP2E1, TAA reduces the degradation of CYP2E1 in
hepatocytes. Therefore, the lack of change in the protein
concentrations of CYP2E1 (Figure 4B), compared with the
TAA-induced reductions in the microsomal total P450
(Figure 3A), CYP2D (Figure 4A) and CYP3A (Figure 4C)
proteins, might, at least in part, be due to the stabilizing
effects of TAA on CYP2E1. Further, the catalytic cycling
of CYP2E1, resulting in its fast degradation, is dependent
on the activity of NADPH-dependent CPR.42 Therefore, a
30% reduction in the CPR activity in our cirrhosis model
(Figure 3B) may also have contributed selectively to the
lack of reduction of CYP2E1 protein in our model.
The in vitro studies using liver microsomes from
TAA-induced liver cirrhosis conducted here and in previous reports18,19 only address the effects of cirrhosis on the
metabolic activity of P450 enzymes. However, the metabolism of drugs by the liver after their in vivo administration is affected by other parameters, such as hepatic
blood flow and degree of protein binding of drugs, in
addition to the metabolic activity of P450.44 It is known
that liver cirrhosis causes intra- and extra-hepatic portosystemic shunting and reduction in the hepatic blood
flow.6 Additionally, liver cirrhosis causes a reduction in
the synthesis of albumin, which is responsible for the
binding of most drugs in plasma.6 The cirrhosisassociated changes in the metabolic activity of P450
enzymes, hepatic blood flow and degree of protein binding of drugs can have varying and complex effects on the
hepatic clearance and bioavailability of drugs, depending
on the extent of hepatic extraction ratio of drug and its
route of administration.6 Although some studies have
shown the effects of cirrhosis induced by ip injection of
TAA on the in vivo metabolism of drugs,20 future studies
could shed more light on the suitability of the model to
investigate the effects of liver cirrhosis on the in vivo
pharmacokinetics of drugs.
The cirrhosis-induced declines in the total P450 content (Figure 3A) and protein (Figure 4) and activities
(Figure 6 and Table 3) of CYP2D, CYP2E1 and CYP3A
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observed in our TAA model in rats are consistent with
the effects of cirrhosis on the total P450 and these isoenzymes reported before in human beings.38,45–48 For
instance, the 50% reduction in total P450 content in our
experimental model (Figure 3A) is similar to the extent of
reduction in the total P450 contents in patients with
severe liver cirrhosis.47,48 Additionally, similar to our
results with CYP3A (Figures 4 and 6 and Table 3), previous studies45,47 reported significant reductions in the
in vitro protein content and activity of CYP3A4 in
patients with liver cirrhosis. Further, in agreement with
our in vitro activity results (Figure 6), the in vivo
metabolism of the CYP3A4 substrate midazolam,46
CYP2E1 substrate chlorzoxazone38 and CYP2D6 substrate debrisoquine38 were significantly lower in patients
with liver cirrhosis. However, as noted before, the in vivo
results may be affected by other parameters, such as
cirrhosis-induced changes in the liver blood flow and/or
degree of protein binding of the drugs, in addition to
reductions in the activity of isoenzymes. Additionally, different isoforms of the same P450 subfamily may be
affected in rats versus human beings (e.g., CYP2D1 in rats
versus CYP2D6 in human beings).
Among the P450 probes used in this study, dextromethorphan O-demethylation, which is commonly used as
an indication of CYP2D activity, was best described by a
two-enzyme system (Table 3). However, the intrinsic
clearance (VMAX/KM) of the high-affinity enzyme, which
is likely related to CYP2D, was >20 times higher than
that for the low-affinity component (Table 3). This observation is in complete agreement with a previous study,49
which reported a two-enzyme system for dextromethorphan O-demethylation in the Sprague–Dawley rat liver
microsomes. Similar to our findings, the high-affinity
component of dextromethorphan O-demethylation in
that study constituted 98% of the total intrinsic clearance
of the pathway.
In conclusion, a TAA model of liver cirrhosis in rats
using chronic ip injection of the chemical for 10 weeks,
followed by a 10-day washout period, caused substantial
fibrosis and cirrhosis in the liver of these animals. Similar
to human cirrhosis, the levels of total P450 and the
protein levels or activities of several P450 enzymes were
significantly reduced in this model. The model may be
suitable for investigations of the mechanisms of the
effects of liver cirrhosis on the in vivo pharmacokinetics
of drugs used in this patient population.
ACK NO WLE DGE MEN TS
This study was partially funded by Chapman University
School of Pharmacy and a Postdoctoral Research Fellowship Award from the American Liver Foundation to
Barent DuBois.

CHANDRASHEKAR ET AL.

CONFLICT OF INTEREST
The authors declare no conflict of interest.
ORCID
Reza Mehvar

https://orcid.org/0000-0002-1770-0391

RE FER EN CES
1. Tapper EB, Ufere NN, Huang DQ, Loomba R. Review article:
current and emerging therapies for the management of cirrhosis and its complications. Aliment Pharmacol Ther. 2022;55(9):
1099-1115. doi:10.1111/apt.16831
2. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, De La
Cuesta FS. Spanish collaborative study group on therapeutic
management in liver disease. Multicenter hospital study on
prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 2002;58(6):435-440.
doi:10.1007/s00228-002-0474-1
3. Lucena MI, Andrade RJ, Tognoni G, Hidalgo R, Sanchez de la
Cuesta F. Spanish collaborative study group on therapeutic
management of liver diseases. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin
Pharmacol. 2003;59(1):71-76. doi:10.1007/s00228-003-0586-2
4. Duthaler U, Bachmann F, Suenderhauf C, et al. Liver cirrhosis
affects the pharmacokinetics of the six substrates of the basel
phenotyping cocktail differently. Clin Pharmacokinet. 2022;
61(7):1039-1055. doi:10.1007/s40262-022-01119-0
5. Weersink RA, Burger DM, Hayward KL, Taxis K, Drenth JPH,
Borgsteede SD. Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations.
Expert Opin Drug Metab Toxicol. 2020;16(1):45-57. doi:10.1080/
17425255.2020.1702022
6. Verbeeck RK. Pharmacokinetics and dosage adjustment in
patients with hepatic dysfunction. Eur J Clin Pharmacol. 2008;
64(12):1147-1161. doi:10.1007/s00228-008-0553-z
7. Franz CC, Hildbrand C, Born C, Egger S, Ratz Bravo AE,
Krahenbuhl S. Dose adjustment in patients with liver cirrhosis: impact on adverse drug reactions and hospitalizations. Eur
J Clin Pharmacol. 2013;69(8):1565-1573. doi:10.1007/s00228013-1502-z
8. Guerra RR, Trotta MR, Aloia TPA, Dagli MLZ, HernandezBlazquez FJ. A novel chronic cirrhosis TAA-induced model in
rats. Braz J Vet Pathol. 2010;3:9-16.
9. Wallace MC, Hamesch K, Lunova M, et al. Standard operating
procedures in experimental liver research: thioacetamide
model in mice and rats. Lab Anim. 2015;49(1_suppl):21-29.
doi:10.1177/0023677215573040
10. Oe S, Fukunaka Y, Hirose T, Yamaoka Y, Tabata Y. A trial on
regeneration therapy of rat liver cirrhosis by controlled release
of hepatocyte growth factor. J Control Release. 2003;88(2):
193-200. doi:10.1016/S0168-3659(02)00463-7
11. Liu Y, Meyer C, Xu C, et al. Animal models of chronic liver
diseases. Am J Physiol Gastrointest Liver Physiol. 2013;304(5):
G449-G468. doi:10.1152/ajpgi.00199.2012
12. Ingawale DK, Mandlik SK, Naik SR. Models of hepatotoxicity
and the underlying cellular, biochemical and immunological
mechanism(s): a critical discussion. Environ Toxicol Pharmacol. 2014;37(1):118-133. doi:10.1016/j.etap.2013.08.015
13. Faccioli LAP, Dias ML, Paranhos BA, Dos Santos
Goldenberg RC. Liver cirrhosis: an overview of experimental

17427843, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/bcpt.13813 by Chapman University, Wiley Online Library on [28/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

12

14.

15.

16.

17.

18.

19.

20.

21.

22.

23.

24.

25.

26.

27.

28.

models in rodents. Life Sci. 2022;301:120615. doi:10.1016/j.lfs.
2022.120615
Ghosh Dastidar S, Warner JB, Warner DR, McClain CJ,
Kirpich IA. Rodent models of alcoholic liver disease: role of
binge ethanol administration. Biomolecules. 2018;8.
Laleman W, Vander Elst I, Zeegers M, et al. A stable model of
cirrhotic portal hypertension in the rat: thioacetamide revisited. Eur J Clin Invest. 2006;36(4):242-249. doi:10.1111/j.13652362.2006.01620.x
Muller D, Sommer M, Kretzschmar M, et al. Lipid peroxidation in thioacetamide-induced macronodular rat liver cirrhosis. Arch Toxicol. 1991;65(3):199-203. doi:10.1007/BF02307309
Corbin IR, Minuk GY. Serial percutaneous liver biopsies in
laboratory rats. Dig Dis Sci. 2003;48(10):1939-1943. doi:10.
1023/A:1026228018643
Xie Y, Wang G, Wang H, et al. Cytochrome P450 dysregulations in thioacetamide-induced liver cirrhosis in rats and the
counteracting effects of hepatoprotective agents. Drug Metab
Dispos. 2012;40(4):796-802. doi:10.1124/dmd.111.043539
Nakajima M, Iwata K, Yamamoto T, Funae Y, Yoshida T,
Kuroiwa Y. Nicotine metabolism in liver microsomes from rats
with acute hepatitis or cirrhosis. Drug Metab Dispos. 1998;
26(1):36-41.
Kaneko H, Otsuka Y, Katagiri M, et al. Reassessment of monoethylglycinexylidide as preoperative liver function test in a rat
model of liver cirrhosis and man. Clin Exp Med. 2001;1(1):
19-26. doi:10.1007/s10238-001-8005-4
Hunter AL, Holscher MA, Neal RA. Thioacetamide-induced
hepatic necrosis. I. Involvement of the mixed-function oxidase
enzyme system. J Pharmacol Exp Ther. 1977;200(2):439-448.
Matsuura Y, Takizawa Y, Fukuda T, Yoshida T, Kuroiwa Y.
Induction of heme oxygenase and inhibition of deltaaminolevulinic acid synthetase of rat liver by thioacetamide
and thioacetamide-S-oxide. J Pharmacobiodyn. 1983;6(5):
340-345. doi:10.1248/bpb1978.6.340
Kraul H, Zimmermann T, Pocha C, Truckenbrodt J,
Hoffmann A. Cytochrome P-450-dependent biotransformation
in Uje:WIST rats with chronic liver injury induced by thioacetamide. Z Versuchstierkd. 1989;32(6):269-273.
Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U,
Lykkesfeldt J. BCPT policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol. 2021;128(1):4-8. doi:10.1111/
bcpt.13492
Knodell RG, Ishak KG, Black WC, et al. Formulation and
application of a numerical scoring system for assessing
histological activity in asymptomatic chronic active hepatitis.
Hepatology. 1981;1(5):431-435. doi:10.1002/hep.1840010511
Brunt EM. Grading and staging the histopathological lesions
of chronic hepatitis: the Knodell histology activity index and
beyond. Hepatology. 2000;31(1):241-246. doi:10.1002/hep.
510310136
Guengerich FP, Martin MV, Sohl CD, Cheng Q. Measurement
of cytochrome P450 and NADPH-cytochrome P450 reductase.
Nat Protoc. 2009;4(9):1245-1251. doi:10.1038/nprot.2009.121
Omura T, Sato R. The carbon monoxide-binding pigment of
the liver microsomes. Evidence for its hemoprotein nature.
J Biol Chem. 1964;239(7):2370-2378. doi:10.1016/S0021-9258
(20)82244-3

13

29. Waxman DJ, Chang TK. Use of 7-ethoxycoumarin to monitor
multiple enzymes in the human CYP1, CYP2, and CYP3 families. In: Phillips IR, Shephard EA, eds. Cytochrome P450 Protocols Methods Mol Biol. Totowa, NJ: Humana Press; 2006:
153-156.
30. Walsky RL, Obach RS. Validated assays for human cytochrome P450 activities. Drug Metab Dispos. 2004;32(6):647-660.
doi:10.1124/dmd.32.6.647
31. Gorski JC, Hall SD, Jones DR, VandenBranden M,
Wrighton SA. Regioselective biotransformation of midazolam
by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol. 1994;47(9):1643-1653. doi:10.1016/
0006-2952(94)90543-6
32. Low TY, Leow CK, Salto-Tellez M, Chung MC. A proteomic
analysis of thioacetamide-induced hepatotoxicity and cirrhosis
in rat livers. Proteomics. 2004;4(12):3960-3974. doi:10.1002/
pmic.200400852
33. Hao H, Zhang L, Jiang S, et al. Thioacetamide intoxication
triggers transcriptional up-regulation but enzyme inactivation
of UDP-glucuronosyltransferases. Drug Metab Dispos. 2011;
39(10):1815-1822. doi:10.1124/dmd.111.039172
34. Johnston DE. Special considerations in interpreting liver function tests. Am Fam Physician. 1999;59(8):2223-2230.
35. Bastien MC, Leblond F, Pichette V, Villeneuve JP. Differential
alteration of cytochrome P450 isoenzymes in two experimental
models of cirrhosis. Can J Physiol Pharmacol. 2000;78(11):
912-919. doi:10.1139/y00-066
36. Porter WR, Gudzinowicz MJ, Neal RA. Thioacetamideinduced hepatic necrosis. II. Pharmacokinetics of thioacetamide and thioacetamide-S-oxide in the rat. J Pharmacol Exp
Ther. 1979;208(3):386-391.
37. Branch RA. Drugs in liver disease. Clin Pharmacol Ther. 1998;
64(4):462-465. doi:10.1016/S0009-9236(98)90077-7
38. Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450–mediated metabolism. Clin
Pharmacol Ther. 2006;80(3):235-245. doi:10.1016/j.clpt.2006.
05.006
39. El-Khateeb E, Achour B, Al-Majdoub ZM, Barber J, RostamiHodjegan A. Non-uniformity of changes in drug-metabolizing
enzymes and transporters in liver cirrhosis: implications for
drug dosage adjustment. Mol Pharm. 2021;18(9):3563-3577.
doi:10.1021/acs.molpharmaceut.1c00462
40. El-Khateeb E, Achour B, Scotcher D, et al. Scaling factors for
clearance in adult liver cirrhosis. Drug Metab Dispos. 2020;
48(12):1271-1282. doi:10.1124/dmd.120.000152
41. Wauthier V, Verbeeck RK, Buc CP. Age-related changes in the
protein and mRNA levels of CYP2E1 and CYP3A isoforms as
well as in their hepatic activities in Wistar rats. What role for
oxidative stress? Arch Toxicol. 2004;78(3):131-138. doi:10.1007/
s00204-003-0526-z
42. Zhukov A, Ingelman-Sundberg M. Relationship between cytochrome P450 catalytic cycling and stability: fast degradation of
ethanol-inducible cytochrome P450 2E1 (CYP2E1) in hepatoma cells is abolished by inactivation of its electron donor
NADPH-cytochrome P450 reductase. Biochem J. 1999;
340(Pt 2):453-458. doi:10.1042/bj3400453
43. Hajovsky H, Hu G, Koen Y, et al. Metabolism and toxicity of
thioacetamide and thioacetamide S-oxide in rat hepatocytes.

17427843, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/bcpt.13813 by Chapman University, Wiley Online Library on [28/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

CHANDRASHEKAR ET AL.

44.

45.

46.

47.

48.

CHANDRASHEKAR ET AL.

Chem Res Toxicol. 2012;25(9):1955-1963. doi:10.1021/
tx3002719
Mehvar R. Clearance concepts: fundamentals and application
to pharmacokinetic behavior of drugs. J Pharm Pharm Sci.
2018;21(1s):88s-102s. doi:10.18433/jpps29896
Yang LQ, Li SJ, Cao YF, et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of
patients with chronic liver diseases. World J Gastroenterol.
2003;9(2):359-363. doi:10.3748/wjg.v9.i2.359
Albarmawi A, Czock D, Gauss A, et al. CYP3A activity in
severe liver cirrhosis correlates with Child-Pugh and model for
end-stage liver disease (MELD) scores. Br J Clin Pharmacol.
2014;77(1):160-169. doi:10.1111/bcp.12182
George J, Murray M, Byth K, Farrell GC. Differential alterations of cytochrome P450 proteins in livers from patients with
severe chronic liver disease. Hepatology. 1995;21(1):120-128.
Farrell GC, Cooksley WG, Powell LW. Drug metabolism in
liver disease: activity of hepatic microsomal metabolizing
enzymes. Clin Pharmacol Ther. 1979;26(4):483-492. doi:10.
1002/cpt1979264483

49. Kerry NL, Somogyi AA, Mikus G, Bochner F. Primary and secondary oxidative metabolism of dextromethorphan. In vitro
studies with female Sprague-Dawley and Dark Agouti rat liver
microsomes. Biochem Pharmacol. 1993;45(4):833-839. doi:10.
1016/0006-2952(93)90166-T

How to cite this article: Chandrashekar DV,
DuBois BN, Rashid M, Mehvar R. Effects of
chronic cirrhosis induced by intraperitoneal
thioacetamide injection on the protein content and
Michaelis–Menten kinetics of cytochrome P450
enzymes in the rat liver microsomes. Basic Clin
Pharmacol Toxicol. 2022;1‐14. doi:10.1111/bcpt.
13813

17427843, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1111/bcpt.13813 by Chapman University, Wiley Online Library on [28/11/2022]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

14

